Sanjiv Navangul has led global pharmaceutical companies to success by mentoring and cultivating a values-driven culture. He has served on the board of Johnson & Johnson Pvt Ltd. India and Fulford India. He has held several leadership roles, including those of Managing Director for Janssen (Pharmaceutical Division of Johnson & Johnson) in India and South Asia; Managing Director for MSD Pharmaceuticals, Philippines; and Commercial Director for MSD India and South Asia. He served as the Vice President of OPPI (Organisation of Pharmaceutical Producers of India) from 2014 to 2019 and was Chairman of the AMCHAM Pharma committee (American Chamber of Commerce) from 2016 to 2019.
Under his leadership, BSV has been ranked 41st amongst Top Companies by AIOCD AWACS in Sept 2020 and one of the Top 10 Biopharma Companies in India (Biospectrum & ABLE).
In 2022, Sanjiv was awarded CEO of the Year at the 8th ILSC Awards. In 2021, he was honored with the Maharashtra Achievers Awards for his outstanding contribution to healthcare and pharma. And in 2020, he was recognized as one of Asia’s top 25 healthcare technology CEOs by The Healthcare Technology CEOs of Asia. Sanjiv is a recipient of a number of industry awards on Public Health, Marketing and Diversity. Recently he was recognized as “Impactful CEO of the Year 2023” by The Economic Times.